Log in
NYSE:BDX

Becton, Dickinson and Competitors

$228.48
-3.39 (-1.46 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$227.69
Now: $228.48
$233.41
50-Day Range
$231.13
MA: $237.16
$244.24
52-Week Range
$197.75
Now: $228.48
$286.72
Volume1.50 million shs
Average Volume1.87 million shs
Market Capitalization$66.23 billion
P/E Ratio83.69
Dividend Yield1.36%
Beta0.83

Competitors

Becton, Dickinson and (NYSE:BDX) Vs. ABT, MDT, SYK, ISRG, EW, and BSX

Should you be buying BDX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Becton, Dickinson and, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Edwards Lifesciences (EW), and Boston Scientific (BSX).

Becton, Dickinson and (NYSE:BDX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Dividends

Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has increased its dividend for 49 consecutive years and Abbott Laboratories has increased its dividend for 48 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent ratings for Becton, Dickinson and and Abbott Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
Abbott Laboratories141302.67

Becton, Dickinson and currently has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Abbott Laboratories has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Given Becton, Dickinson and's higher possible upside, analysts plainly believe Becton, Dickinson and is more favorable than Abbott Laboratories.

Earnings & Valuation

This table compares Becton, Dickinson and and Abbott Laboratories' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73

Abbott Laboratories has higher revenue and earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

74.4% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 0.1% of Becton, Dickinson and shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Becton, Dickinson and has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Becton, Dickinson and and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Abbott Laboratories10.50%18.19%8.29%

Summary

Abbott Laboratories beats Becton, Dickinson and on 10 of the 18 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 43 consecutive years and Becton, Dickinson and has raised its dividend for 49 consecutive years.

Analyst Ratings

This is a summary of current recommendations and price targets for Medtronic and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Becton, Dickinson and07712.60

Medtronic presently has a consensus target price of $118.1538, suggesting a potential upside of 6.47%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's higher probable upside, analysts clearly believe Becton, Dickinson and is more favorable than Medtronic.

Valuation & Earnings

This table compares Medtronic and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Medtronic has higher revenue and earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Medtronic and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Becton, Dickinson and5.11%13.30%5.60%

Summary

Medtronic beats Becton, Dickinson and on 10 of the 17 factors compared between the two stocks.

Stryker (NYSE:SYK) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Stryker pays out 27.8% of its earnings in the form of a dividend. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years and Becton, Dickinson and has raised its dividend for 49 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Stryker and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Becton, Dickinson and07712.60

Stryker presently has a consensus target price of $221.44, suggesting a potential downside of 4.97%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's stronger consensus rating and higher probable upside, analysts clearly believe Becton, Dickinson and is more favorable than Stryker.

Valuation & Earnings

This table compares Stryker and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Stryker has higher earnings, but lower revenue than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Stryker and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Becton, Dickinson and5.11%13.30%5.60%

Summary

Becton, Dickinson and beats Stryker on 9 of the 17 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Intuitive Surgical and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
Becton, Dickinson and07712.60

Intuitive Surgical presently has a consensus target price of $718.2778, suggesting a potential downside of 0.11%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's stronger consensus rating and higher probable upside, analysts clearly believe Becton, Dickinson and is more favorable than Intuitive Surgical.

Earnings and Valuation

This table compares Intuitive Surgical and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Intuitive Surgical has higher earnings, but lower revenue than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Intuitive Surgical has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Becton, Dickinson and5.11%13.30%5.60%

Summary

Intuitive Surgical beats Becton, Dickinson and on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Edwards Lifesciences and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
Becton, Dickinson and07712.60

Edwards Lifesciences presently has a consensus target price of $87.7222, suggesting a potential upside of 3.57%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's stronger consensus rating and higher probable upside, analysts clearly believe Becton, Dickinson and is more favorable than Edwards Lifesciences.

Earnings and Valuation

This table compares Edwards Lifesciences and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Edwards Lifesciences has higher earnings, but lower revenue than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

79.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Edwards Lifesciences has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Becton, Dickinson and5.11%13.30%5.60%

Summary

Edwards Lifesciences beats Becton, Dickinson and on 9 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Boston Scientific and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.54%5.55%
Becton, Dickinson and5.11%13.30%5.60%

Institutional & Insider Ownership

82.7% of Boston Scientific shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 0.7% of Boston Scientific shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Boston Scientific and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion4.45$4.70 billion$1.5821.09
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Boston Scientific has higher earnings, but lower revenue than Becton, Dickinson and. Boston Scientific is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Boston Scientific and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific031833.00
Becton, Dickinson and07712.60

Boston Scientific presently has a consensus target price of $43.80, suggesting a potential upside of 31.41%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities research analysts clearly believe Boston Scientific is more favorable than Becton, Dickinson and.

Risk & Volatility

Boston Scientific has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Summary

Boston Scientific beats Becton, Dickinson and on 10 of the 15 factors compared between the two stocks.


Becton, Dickinson and Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27-1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97-0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01-0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05-1.6%$84.53 billion$4.48 billion81.90
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70-0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33-1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79-1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77-1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09-1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57-0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89-0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07-1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14-0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09-3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50-0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50-1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43-0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55-0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47-1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78-0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98-0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32-2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18-2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37-2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24-1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90-1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55-2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87-4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14-2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12-2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52-0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40-11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98-1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94-1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.